摘要
目的:探讨雷替曲塞在肝癌肝动脉化疗栓塞术(TACE)治疗中的近期疗效和安全性。方法:选取我院2011年12月至2015年06月收治的42例无外科切除适应证的肝癌患者,将其随机分为观察组(21例)和对照组(21例),观察组给予雷替曲塞(3 mg/m^2)联合奥沙利铂(100 mg/m^2)、表柔比星(40 mg/m^2)行肝动脉化疗栓塞术治疗,对照组给予5-FU(500 mg/m^2)联合奥沙利铂(100 mg/m^2)、表柔比星(40 mg/m^2)行肝动脉化疗栓塞术治疗。以上治疗每4~6周1次,末次随访时间为2016年06月30日。观察两组的治疗有效率(RR)、疾病控制率(DCR)、无进展生存期(PFS)及不良反应。结果:观察组和对照组的RR分别为76.19%、38.10%,DCR分别为95.24%、66.67%,平均PFS分别为11.57个月、7.87个月,差异均有统计学意义(P<0.05)。两组不良反应主要为腹痛、恶心、呕吐、骨髓抑制、发热、转氨酶升高等,差异均无统计学意义(P>0.05)。结论:雷替曲塞联合肝动脉化疗栓塞术,可使肝癌患者获益,不良反应可接受。
Objective：To investigate the short term efficacy and side effects of raltitrexed in transcatheter arterial chemoembolization treatment of hepatic carcinoma.Methods：42 cases of patients with inoperable hepatic carcinomas in our hospital from December 2011 to June 2015,were randomly divided into observation group （21 cases） and control group （21 cases）.Patients in observation group were treated with TACE using raltitrexed （3 mg/m^2） combined with oxaliplatin （100 mg/m^2） and epirubicin （40 mg/m^2）,while patients in control group were treated with TACE using 5-FU（500 mg/m^2） combined with oxaliplatin （100 mg/m^2） and epirubicin （40 mg/m^2）.Repeated treatment was given every 4～6 weeks.The end of the follow-up period was June 30,2016.The response rate （RR）,disease control rate （DCR）,progression free survival （PFS） and the side effects were assessed,and the results were compared between the two groups.Results：The RRs of the observation group and control group were 76.19% and 38.10% respectively.The DCRs of the observation group and control group were 95.24% and 66.67% respectively.The mean progression free survival of the observation group and control group were 11.57 months and 7.87 months respectively.All the differences were statistically significant （P〈0.05）.The main side effects in both groups were abdominal pain,nausea,vomiting,bone marrow suppression,fever and elevation of transaminase,but the differences between the two groups were not statistically significant （P〉0.05）.Conclusion：Patients with hepatic carcinoma may benefit from the treatment of TACE using raltitrexed.The side effects can be tolerated by the patients.
出处
《现代肿瘤医学》
CAS
2018年第7期1067-1069,共3页
Journal of Modern Oncology
关键词
肝癌
雷替曲塞
肝动脉化疗栓塞术
hepatic carcinoma
raltitrexed
transcatheter arterial chemoembolization
